Mode
Text Size
Log in / Sign up
Phase 3 N=50 Treatment

MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication

Uterine Leiomyoma · Uterine Fibroids

Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Feb 2019
Primary outcome: Primary: Number of Adverse Events — 77; 75 Adverse Events

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
ExAblate Enhanced Sonication (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
InSightec
Primary completion
Aug 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Adverse Events
77; 75

Summary

This is a phase 3 study to determine the safety of the new features to the FDA approved ExAblate device using a new method to ablate fibroids deemed Enhanced Sonication.

Eligibility Criteria

Inclusion Criteria

  • Women age 18 or older, who present with symptomatic fibroids
  • Women who have given written informed consent
  • Women who are able and willing to attend all study visits.
  • Patient is pre or peri-menopausal (within 12 months of last menstrual period).
  • Able to communicate sensations during the ExAblate procedure.
  • Uterine fibroids, which are device accessible (i.e., positioned in the uterus such that they can be accessed without being shielded by bowel or bone).
  • Fibroids(s) clearly visible on non-contrast MRI.

Exclusion Criteria

  • Women who are pregnant, as confirmed by serum test at time of screening, or urine pregnancy test on the day of treatment
  • Patient who desire to become pregnant in the future.
  • Patients who are breast-feeding.
  • Patients with an active pelvic inflammatory disease (PID)
  • Active local or systemic infection
  • Metallic implants that are incompatible with MRI
  • Known intolerance to the MRI contrast agent (e.g. Gadolinium or Magnevist)
  • Severe claustrophobia that would prevent completion of procedure in the MR unit.
  • Extensive abdominal scarring in the beam pass or dermoid cyst of the ovary anywhere in the treatment path.
  • Known or suspected pelvic carcinoma or pre-malignant conditions, including sarcoma and adenomatous hyperplasia.
  • Pedunculated fibroids.
  • Intrauterine device (IUD) anywhere in the treatment path
  • Undiagnosed vaginal bleeding.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00365989). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search